Abstract
Aripiprazole, which is approved for schizophrenia (ages 13–17) and acute manic or mixed episodes associated with bipolar I (10–17 years) in pediatric patients, might help children with spontaneous episodes of elevated mood and/or irritability who are at high genetic risk for bipolar disorder due to genetics, according to a randomized controlled trial (RCT).
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callMore From: The Brown University Child and Adolescent Behavior Letter
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
